University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln
Virology Papers

Virology, Nebraska Center for

2022

Immunogenicity and Protective Efficacy of a Recombinant
Pichinde Viral-Vectored Vaccine Expressing Influenza Virus
Hemagglutinin Antigen in Pigs
Sushmita Kumari
University of Nebraska-Lincoln, skumari2@huskers.unl.edu

Jayeshbhai Chaudhari
University of Nebraska-Lincoln, jayeshvet03@huskers.unl.edu

Qinfeng Huang
University of Minnesota

Phillip Gauger
Iowa State University

Marcelo Nunes De Almeida
Iowa State University
Follow this and additional works at: https://digitalcommons.unl.edu/virologypub
See next page for additional authors
Part of the Biological Phenomena, Cell Phenomena, and Immunity Commons, Cell and Developmental
Biology Commons, Genetics and Genomics Commons, Infectious Disease Commons, Medical
Immunology Commons, Medical Pathology Commons, and the Virology Commons

Kumari, Sushmita; Chaudhari, Jayeshbhai; Huang, Qinfeng; Gauger, Phillip; Nunes De Almeida, Marcelo;
Liang, Yuying; Ly, Hinh; and Vu, Hiep, "Immunogenicity and Protective Efficacy of a Recombinant Pichinde
Viral-Vectored Vaccine Expressing Influenza Virus Hemagglutinin Antigen in Pigs" (2022). Virology
Papers. 489.
https://digitalcommons.unl.edu/virologypub/489

This Article is brought to you for free and open access by the Virology, Nebraska Center for at
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Virology Papers by an
authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

Authors
Sushmita Kumari, Jayeshbhai Chaudhari, Qinfeng Huang, Phillip Gauger, Marcelo Nunes De Almeida,
Yuying Liang, Hinh Ly, and Hiep Vu

This article is available at DigitalCommons@University of Nebraska - Lincoln: https://digitalcommons.unl.edu/
virologypub/489

Article

Immunogenicity and Protective Efficacy of a Recombinant
Pichinde Viral-Vectored Vaccine Expressing Influenza Virus
Hemagglutinin Antigen in Pigs
Sushmita Kumari 1,2 , Jayeshbhai Chaudhari 1,2 , Qinfeng Huang 3 , Phillip Gauger 4 ,
Marcelo Nunes De Almeida 4 , Yuying Liang 3 , Hinh Ly 3, * and Hiep L. X. Vu 1,5, *
1
2

3

4

5

*

Citation: Kumari, S.; Chaudhari, J.;
Huang, Q.; Gauger, P.; De Almeida,
M.N.; Liang, Y.; Ly, H.; Vu, H.L.X.
Immunogenicity and Protective
Efficacy of a Recombinant Pichinde
Viral-Vectored Vaccine Expressing
Influenza Virus Hemagglutinin
Antigen in Pigs. Vaccines 2022, 10,
1400. https://doi.org/10.3390/
vaccines10091400
Academic Editor: Bapi Pahar
Received: 14 July 2022
Accepted: 22 August 2022

Nebraska Center for Virology, University of Nebraska-Lincoln, Lincoln, NE 68583, USA
School of Veterinary Medicine and Biomedical Sciences, University of Nebraska-Lincoln,
Lincoln, NE 68583, USA
Veterinary & Biomedical Sciences Department, College of Veterinary Medicine, University of Minnesota,
Twin Cities, MN 55108, USA
Veterinary Diagnostic Laboratory, College of Veterinary Medicine, Iowa State University,
Ames, IA 50011, USA
Department of Animals Sciences, University of Nebraska-Lincoln, Lincoln, NE 68583, USA
Correspondence: hly@umn.edu (H.L.); hiepvu@unl.edu (H.L.X.V.);
Tel.: +1-612-625-3358 (H.L.); +1-402-472-4528 (H.L.X.V.)

Abstract: Influenza A virus of swine (IAV-S) is an economically important swine pathogen. The
IAV-S hemagglutinin (HA) surface protein is the main target for vaccine development. In this study,
we evaluated the feasibility of using the recombinant tri-segmented Pichinde virus (rPICV) as a
viral vector to deliver HA antigen to protect pigs against IAV-S challenge. Four groups of weaned
pigs (T01–T04) were included in the study. T01 was injected with PBS to serve as a non-vaccinated
control. T02 was inoculated with rPICV expressing green fluorescence protein (rPICV-GFP). T03
was vaccinated with rPICV expressing the HA antigen of the IAV-S H3N2 strain (rPICV-H3). T04
was vaccinated with the recombinant HA protein antigen of the same H3N2 strain. Pigs were
vaccinated twice at day 0 and day 21 and challenged at day 43 by intra-tracheal inoculation with the
homologous H3N2 IAV-S strain. After vaccination, all pigs in T03 and T04 groups were seroconverted
and exhibited high titers of plasma neutralizing antibodies. After challenge, high levels of IAV-S RNA
were detected in the nasal swabs and bronchioalveolar lavage fluid of pigs in T01 and T02 but not in
the T03 and T04 groups. Similarly, lung lesions were observed in T01 and T02, but not in the T03 and
T04 groups. No significant difference in terms of protection was observed between the T03 and T04
group. Collectively, our results demonstrate that the rPICV-H3 vectored vaccine elicited protective
immunity against IAV-S challenge. This study shows that rPICV is a promising viral vector for the
development of vaccines against IAV-S.
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1. Introduction
Influenza A virus of swine (IAV-S) is one of the most important respiratory pathogens
of swine [1]. The virus is widespread worldwide, causing significant economic loss to swine
producers [2]. Clinically, pigs infected with IAV-S often display signs of an acute respiratory
disease that rapidly resolves after 7 or 10 days of infection. However, when associated
with other pathogens of the porcine respiratory disease complex, IAV-S infection can often
lead to severe pneumonia [3]. There are three known major subtypes of IAV-S affecting
pigs: H1N1, H1N2, and H3N2. Based on phylogenetic analysis of the IAV-S hemagglutinin
(HA) sequences, the H1 and H3 subtypes can be further classified into multiple clades or
lineages that are genetically distant from one another [4–7]. New strains of influenza virus

4.0/).

Vaccines 2022, 10, 1400. https://doi.org/10.3390/vaccines10091400

https://www.mdpi.com/journal/vaccines

Vaccines 2022, 10, 1400

2 of 14

frequently emerge in swine herds [8]. Genetic diversity of IAV-S represents a major hurdle
for developing an efficacious vaccine [9–11].
Different platforms have been considered and used towards the development of
vaccines against IAV [12]. Polyvalent, whole-inactivated virus (WIV) [13] vaccines are
commonly used for the control of IAV-S infection [14]. The WIV vaccines are found to be
effective in protecting vaccinated pigs against antigenically matched IAV-S strains, but
vaccine efficacy dramatically decreases when vaccinated pigs are exposed to antigenically
mismatched virus strains [15–17]. Additionally, the use of WIV vaccines may enhance the
severity of clinical outcomes if the vaccinated pigs are subsequently exposed to mismatched
IAV-S strains of the same subtype [16,18], a phenomenon known as vaccine-associated
enhanced respiratory disease (VAERD). Recently, a live-attenuated virus (LAV) vaccine
against IAV-S was licensed for clinical application [19,20]. Experimental data demonstrate
that the LAV vaccine could confer better heterologous protection than WIV vaccines [21–23].
However, reassortment between LAV and field IAV-S isolates has been documented, raising
a real concern regarding the safety of the LAV vaccine platform [24].
HA is an important target for the development of IAV-S vaccines. Different forms of
the HA antigen have been tested in pigs as subunit vaccines, including HA protein- and
DNA-based vaccines as well as viral vector-based vaccines expressing HA [25–30]. Several
viral vectors have been employed to deliver HA antigen in pigs that include but are not
limited to replication-defective human adenovirus type 5 (Ad5) and Orf virus [31,32].
We are interested in developing Pichinde virus (PICV) as a viral vector to deliver HA
antigen in pigs. PICV is an enveloped RNA virus within the Arenaviridae family. The virus
was first isolated from rice rats (Oryzomys albigularis) in Colombia, South America [33].
PICV is considered non-pathogenic as there are no known PICV-associated diseases in
humans or other animals [34]. The virus can infect a wide range of cell types from diverse
host animal species that may include but are not necessarily limited to human, mouse,
monkey, and avian species [34–37]. The wide host ranges and avirulent nature of PICV
makes it a promising viral vector for flexible delivery of vaccine immunogens in humans
and various animal species.
A reverse genetics system has recently been developed to generate recombinant trisegment PICV (rPICV) that carries as its genome two different small genomic (S) segments
that encode the nucleoprotein (NP) and glycoprotein precursor complex (GPC), respectively,
in each of the S segments and a long (L) segment that encodes the Z matrix protein and the L
RNA-dependent RNA polymerase (RdRp). Additionally, the genome of the tri-segmented
rPICV has been engineered to accommodate up to two foreign genes that can be used as
vaccine antigens [34]. For instance, both HA and NP genes of a laboratory-adapted IAV
strain PR8 have been simultaneously inserted into the rPICV genome to produce a rPICV
vectored vaccine that express IAV HA and NP concomitantly. When administered into
mice, this experimental vaccine induces high levels of HA-specific neutralizing antibodies
and NP-specific T cell response and protects the mice against a lethal challenge with IAV
PR8 infection [34]. Another rPICV vectored vaccine expressing turkey arthritis reovirus
antigens has also been generated and shown to induce high serum neutralizing antibody
titers compared with the nonimmunized turkey poults [36].
In the present study, a rPICV vectored vaccine expressing the HA antigen of an IAV-S
H3N2 strain (designated rPICV-H3) was generated. High levels of the H3 antigen were
expressed in different pig cell types that were infected with rPICV-H3. Pigs vaccinated with
the rPICV-H3 vaccine developed high titers of neutralizing antibody and were protected
against a challenge infection with the homologous IAV-S H3N2 strain. Collectively, this
study provides a proof of concept that rPICV can successfully be used as a viral vector for
anti-influenza vaccination.
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2. Materials and Methods
2.1. Cells, Reagents, and Viruses
Baby hamster kidney (BHK-21) and porcine kidney-15 (PK-15) cells were cultured in
complete Dulbecco’s Modified Eagle Medium (DMEM) (Life Technologies, Grand Island,
NY, USA), supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich, St. Louis,
MO, USA) and 1× penicillin–streptomycin (100 units/mL of penicillin and 100 µg/mL of
streptomycin, Life Technologies, Grand Island, NY, USA). Porcine alveolar macrophages
(PAMs) were collected from lung lavage of pigs between 4 and 8 weeks old and were
cryopreserved in a cell freezing medium containing 40% Roswell Park Memorial Institute
(RPMI) (Life Technologies, Grand Island, NY, USA), 50% FBS, and 10% dimethyl sulfoxide.
When needed, the cells were revived and cultured in complete RPMI supplemented with
10% FBS and 1× penicillin–streptomycin. Madin–Darby Canine Kidney (MDCK) cells were
cultured in DMEM supplemented with 10% FBS, 1× penicillin–streptomycin, 0.2% Bovine
serum albumin (BSA, Sigma-Aldrich, Saint Louis, MO, USA), and 25 mM HEPES (Hyclone,
Life Technologies, Grand Island, NY, USA). All cell cultures were incubated at 37 ◦ C in a
humidified environment containing 5% CO2.
The IAV-S strain A/swine/Texas/4199-2/1998 (H3N2 TX98) was obtained from
The National Veterinary Services Laboratories (NVSL, Ames, IA, USA). The virus was
propagated in MDCK cells in a virus inoculation medium (DMEM) supplemented with
1× penicillin–streptomycin, 0.2% BSA, 25 mM HEPES, and 1 µg/mL TPCK-treated trypsin
(ThermoFisher Scientific, Rockford, IL, USA).
2.2. Experimental Vaccines
The recombinant HA protein of H3N2 TX98 (designated H3-protein) was expressed
in a baculovirus expression system via a contract with Genscript (Piscataway, NJ, USA).
The purified protein was emulsified in 20% (v/v) Emulsigen-DL 90 (Phibro Animal Health
Corporation, Omaha, NE, USA). Each dose of this vaccine contained 100 µg protein in a
total volume of 2 mL.
The rPICV expressing the HA antigen of H3N2 TX98 was constructed as previously
described [34]. Briefly, the HA sequence was codon-optimized for optimal protein expression in pigs using a commercial DNA synthesis service (Genscript, Piscataway, NJ, USA).
The gene was cloned into both S1 and S2 of the rPICV reverse genetics system [34,35]. The
three plasmids containing S1, S2, and L segments were co-transfected into BSRT7 cells to
rescue the rPICV expressing H3 antigen (designated rPICV-H3). The rPICV-H3 vaccine
was amplified in BHK-21 cells, and viral titers were quantified by conventional plaque
assay [34]. A rPICV expressing green fluorescence protein (rPICV-GFP) that was generated
previously [34] was included in this study to serve as a vector control [34].
2.3. Antigen Expression In Vitro
BHK-21, PK-15, or PAMs cultured separately in 24-well plates were infected with
rPICV-H3 and rPICV-GFP at a multiplicity of infection (MOI) of 1 pfu per cell. At 48 h
post-infection (hpi), cells were washed once with PBS and fixed in 500 µL cold solution of
methanol/acetone (1:1 v/v), followed by incubation with a monoclonal antibody specific
to H3 antigen (generated in our laboratory) for 1 h at room temperature (RT). The cells
were washed three times with phosphate buffer saline (PBS, pH 7.4) and incubated with a
donkey anti-mouse Alexa flour 488 IgG H + L (Invitrogen, Life Technology corporation,
Eugene, OR, USA) for 1 h at RT. After another three washes with PBS, fluorescent signals
from cells were observed via an inverted fluorescence microscope. Fluorescent images were
taken using the Nikon Eclipse Ts2R-FL operated by Nikon NIS Elements (ver 5.02). Cells
infected with rPICV-GFP were directly visualized under fluorescence microscope 48 hpi.
All images were taken using a 20× objective.
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vaccinated controls. T02 had 3 pigs that were injected IM with 10 pfu of rPICV-GFP in 2
mL. Pigs in T01 and T02 groups were commingled in the same room throughout the
course of the study. T03 contained five pigs that were vaccinated IM with 2 mL vaccine
formulation containing 106 pfu of rPICV-H3. T04 had five pigs that were vaccinated IM
with 2 mL of the H3-protein subunit vaccine. The pigs were vaccinated twice on days 0
4 of 14
and 21 (Figure 1). One pig from T03 and another from T04 were humanely euthanized
and removed from the study for welfare purposes due to injury during the blood collection process and for other reasons unrelated to rPICV infection, respectively.
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2.5. Serological Assay
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optical density (OD) ratios (S/N ratio). Samples with S/N ratio below 0.6 was considered
positive, as it indicated the presence of higher levels of anti-NP antibodies in the test sample
than in the negative control used in the assay.
Antibody responses against the H3 protein and the GFP were measured using ELISA.
Briefly, flat-bottom 96-well plates were coated overnight at 4 ◦ C with 100 µL of either the
H3 protein or the GFP diluted in PBS to the final concentration of 2 µg/mL or 5 µg/mL,
respectively. After washing with PBS containing 0.1% tween 20 (PBS-T20), the wells were
blocked with 250 µL/well of a blocking buffer (10% skim milk in PBS-T20) for 2 h at RT.
Plasma samples were diluted in an assay buffer (5% skim milk in PBS-T20), and 100 µL of
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diluted sample was added to each well of the plates in duplicate, followed by 1 h incubation
at RT. After three washes with PBS-T20, 100 µL of HRP-labeled goat anti-pig IgG (Sera Care,
Milford, MA, USA) diluted 1:5000 in assay buffer was added to each well followed by
30 min incubation at room temperature. After three washes with PBS-T20, 100 µL of ABTS
substrate (Sera Care, Milford, MA, USA) was added to each well. The plate was incubated
at RT between 5 and 25 min (until color was observed in the positive control wells). The
reaction was stopped by adding 100 µL of 1% sodium dodecyl sulfate (1% SDS) diluted in
distilled water. Optical density (OD) was measured at 405 nm wavelength by an ELISA
plate reader (Bio-Tek ELx808). For the H3 ELISA, samples were diluted 2-fold serially
before adding to the ELISA plates. An arbitrary cutoff value equivalent to mean plus five
standard deviations of the OD values of plasma samples from the non-immunized control
animals was calculated. Antibody titers were determined at the highest dilutions with OD
values above the cutoff value. For GFP- ELISA, plasma samples were tested at the dilution
1:100 and data are presented as the OD405 value of each sample at the 1:100 dilution.
Virus neutralization assay and hemagglutination inhibition assay were essentially
performed as previously described [38].
2.6. Quantification of Viral Load
RNA was extracted from nasal swabs and BALF samples using Quick RNA viral
Kit (Zymo Research, Costa Mesa, CA, USA) according to the manufacturer’s protocol.
Viral genomic copies were quantified using a real-time reverse transcription PCR (RT-PCR)
by VetMax-Gold SIV Detection Kit (Life Technologies, Austin, TX, USA), as previously
described [38]. Chemically synthesized RNA fragment with known copy numbers was
used to establish a standard curve based on which the absolute copy numbers of viral
RNA in each sample was estimated. Viral loads in nasal swabs were reported as log10
copies per µL of RNA used for the RT–PCR reaction. For statistical purposes, samples with
undetectable levels of viral RNA were assigned a zero value.
Infectious IAV-S titers in BALF samples were determined by virus titration assay in
MDCK cells cultured in 96-well plates. Briefly, the samples were diluted 10-fold serially in
the virus inoculation medium, and 100 µL of each dilution was inoculated in each well for a
total of four wells per dilution. An immunofluorescence assay (IFA) was performed at 48 h
to visualize the infected cells, and virus titer was calculated following the Reed–Muench
method for estimating fifty percent endpoint [39].
2.7. Lung Pathological Analysis
Lung gross lesions were evaluated during necropsy by a veterinary pathologist who
was blinded to the treatment groups. The percentage of lung consolidation was calculated
as described previously [40]. Sections of three different lung lobes, cranial, middle, and
caudal, were stained with hematoxylin and eosin (H&E) following a routine pathological
procedure. The slides were evaluated by a veterinary pathologist who was blinded to
treatment groups following the scoring parameters as described previously [22]. Each of
the three lung lobes was scored for six different parameters to generate a composite score
ranging from 0 to 22 as previously described [22].
RNA in situ hybridization (ISH) was performed in the lung sections as previously
described [38]. Composite scoring for the ISH slides was performed similarly to the
composite score for microscopic lesions.
2.8. Statistical Analysis
All statistical analyses were carried out using the GraphPad Prism 9.0. Antibody titers
were log2 transformed and analyzed using the mixed-effects analysis multiple comparisons.
Gross lung lesion score, lung microscopic lesion score, viral genome copies, and virus titers
were analyzed by ordinary one-way analysis of variance (ANOVA), followed by Tukey’s
multiple comparison test.
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pv but not in group T01 (Figure 3A). The result suggests that pigs vaccinated with rPICVGFP did not transmit the virus to induce an anti-GFP antibody response in the contact
3.3. Pigs Immunized with rPICV-H3 or H3-Protein Subunit Vaccines Mounted a Robust
pigs.
Antibody Response

Antibodies specific to the H3 antigen were measured by an indirect ELISA. As expected, H3-specific antibodies were only detected in T03 and T04, not in the T01 and T02
groups (Figure 3B). H3-specific ELISA antibodies were detected in T04 pigs starting from
day 14 pv and continued to increase on days 28 and 35 pv. H3-specific ELISA antibodies
were not detected in T03 pigs until day 28 pv, corresponding to day 7 post-boost. The
results indicate that the H3-protein subunit vaccine elicited faster antibody responses than
the rPICV-H3 vectored vaccine. However, no significant difference in the H3-specific ELISA
antibody titers were observed between T03 and T04 after day 28 pv (corresponding to day 7
post-boost).
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collected to measure IAV-S RNA by using an RT-PCR. High levels of IAV-S RNA were
detected in the BALF from all pigs in T01 and T02 (Figure 4C). In contrast, no IAV-S RNA
was detected in the BALF from any of the pigs in group T04. One out of four pigs in the
T03 group had a detectable level of IAV-S RNA in the BALF. This pig also had IAV-S RNA
in its nasal swab collected on day 4 pc. To determine IAV-S infectivity, samples of BALF 8 of 14
were titrated on MDCK cells. All BALF samples collected from T01 and T02 had infectious
IAV-S with the titers ranging from 104.0 to 105.75 TCID50/mL. In contrast, infectious IAV-S
was not
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in the BALF
of of
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pigs
T03 and
though one
pig than
in thethat
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T04ingroup
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(Figure
4D).
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Figure 4. IAV-S shedding post challenge. (A) IAV-S NP RNA in nasal swab samples as quantified
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challenge infection with IAV-S. (C) IAV-S NP RNA in BALF collected during necropsy at day 5
infection with IAV-S. (C) IAV-S NP RNA in BALF collected during necropsy at day 5 post challenge.
post challenge. (D) Infectious IAV-S in BALF samples measured by virus titration in MDCK cells.
T01—PBS; T02—rPICV-GFP; T03—rPICV-H3; T04—H3-protein. ns—no significance, ** p ≤ 0.01,
*** p ≤ 0.001, **** p ≤ 0.0001.

All pigs were humanely sacrificed at day 5 post challenge, and a BALF sample was
collected to measure IAV-S RNA by using an RT-PCR. High levels of IAV-S RNA were
detected in the BALF from all pigs in T01 and T02 (Figure 4C). In contrast, no IAV-S RNA
was detected in the BALF from any of the pigs in group T04. One out of four pigs in the
T03 group had a detectable level of IAV-S RNA in the BALF. This pig also had IAV-S RNA
in its nasal swab collected on day 4 pc. To determine IAV-S infectivity, samples of BALF
were titrated on MDCK cells. All BALF samples collected from T01 and T02 had infectious
IAV-S with the titers ranging from 104.0 to 105.75 TCID50 /mL. In contrast, infectious IAV-S
was not detected in the BALF of any pigs in T03 and T04, even though one pig in the T03
group had a detectable level of IAV-S RNA as determined by RT-PCR (Figure 4D).
At necropsy, gross lung lesions were evaluated. Mild lung consolidation was observed
in all pigs in the T01 and T02 groups, with the percentage of consolidated lung surface
varying from 1.5% to 8%. Pigs in the T03 and T04 groups did not exhibit any visible lung
consolidation (Figure 5A).
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During necropsy, samples from three lung lobes (apical, middle, and caudal) were
selected for microscopic evaluation. Average composite scores of the three lobes are reported (Figure 5C). Lung sections from the T01 and T02 groups exhibited mild-to-moderate
interstitial pneumonia with necrotizing bronchiolitis and peribronchiolar lymphocytic
cuffing (Figure 5C). The mean composite microscopic scores of the T01 and T02 groups
ranged from 1.7 to 9. On the contrary, no significant microscopic lesions were observed in
the lung sections of pigs in the T03 and T04 groups (Figure 5D).
In situ hybridization (ISH) was used to detect IAV-S NP gene transcript in the cardiac
(middle) lung lobe of all pigs (Figure 5E). NP transcripts were detected in all lung sections
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cuffing (Figure 5C). The mean composite microscopic scores of the T01 and T02 groups
ranged from 1.7 to 9. On the contrary, no significant microscopic lesions were observed in
the lung sections of pigs in the T03 and T04 groups (Figure 5D).
In situ hybridization (ISH) was used to detect IAV-S NP gene transcript in the cardiac
(middle) lung lobe of all pigs (Figure 5E). NP transcripts were detected in all lung sections
10 of 14
of pigs in the T01 and T02 groups. Conversely, no viral NP transcripts were observed
in
any lung section of pigs in the T03 and T04 groups (Figure 5F).
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of pigs in
thefrom
T01 and
groups.
Conversely,
viral NP transcripts
were observed in
protected
pigs
the T02
challenge
infection
with no
a homologous
H3N2 strain.
any lung section of pigs in the T03 and T04 groups (Figure 5F).
Collectively,
demonstrate
both the Vectored
rPICV-H3
or H3-protein
vaccines
3.5. Pigs
Immunized the
withresults
H3-Protein
Vaccine that
or rPICV-H3
Vaccine
Tested Negative
protected
pigs
from
the
challenge
infection
with
a
homologous
H3N2
strain.
for IAV-S NP Antibodies by a Commercial ELISA Kit
specific
IAV-S NP
were or
measured
using
a commercial
ELISA
kit that
3.5.Antibodies
Pigs Immunized
withtoH3-Protein
Vaccine
rPICV-H3
Vectored
Vaccine Tested
Negative
for
is IAV-S
routinely
used for IAV-S
serodiagnosis.
NP Antibodies
by a Commercial
ELISAAll
Kitpigs tested negative for IAV-S NP antibody
before Antibodies
vaccinationspecific
(day -10)
and continued
to be negative
the end of the
study
to IAV-S
NP were measured
usingtill
a commercial
ELISA
kit(day
that 48
is
pv).
The results
demonstrate
that the experimental
vaccines
in this
did not
routinely
used for
IAV-S serodiagnosis.
All pigs tested
negativeused
for IAV-S
NPstudy
antibody
beinduce
antibody against
IAV-S
NP protein.
Thus,
vaccination
withofH-3
protein
or rPICVfore vaccination
(day -10)
and continued
to be
negative
till the end
the study
(day
48 pv).
H3The
vectored
vaccine
does
not
interfere
with
the
serodiagnosis
of
IAV-S
(Figure
6).
results demonstrate that the experimental vaccines used in this study did not induce
antibody against IAV-S NP protein. Thus, vaccination with H-3 protein or rPICV-H3 vectored
vaccine does not interfere with the serodiagnosis of IAV-S (Figure 6).

Figure 6. Antibodies against IAV-S NP protein measured by a blocking ELISA. Data are expressed
as the sample to negative (S/N) ratio. The horizontal dotted line at S/N of 0.6 is the assay cutoff.
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as the sample to negative (S/N) ratio. The horizontal dotted line at S/N of 0.6 is the assay cutoff. Test
T03—rPICV-H3;
T04—H3-protein.
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The main objective of this study was to evaluate the immunogenicity and protective
efficacy of an rPICV viral vector expressing HA antigen of the IAV-S H3N2 strain in pigs
(rPICV-H3). PICV is a non-pathogenic virus that was originally isolated from rats [33].
The viral genome has been engineered to allow it to carry up to two different vaccine immunogens. It has been demonstrated previously that rPICV viral vector effectively delivers
vaccine immunogens in mice and turkeys [34,36]. In the present study, we demonstrated
that pigs immunized with the rPICV-H3 vector vaccine mounted a robust humoral immune
response and were completely protected against challenge infection with the homologous
IAV-S H3N2 strain.
Pathogenesis of PICV infection in pigs has not been studied yet. There is no information pertaining to the target tissue and cell types for PICV replication, routes, and duration
of viral shedding. Hence, we were interested in determining whether the pigs infected

Vaccines 2022, 10, 1400

11 of 14

with rPICV spread the virus. For this purpose, pigs vaccinated with rPICV-GFP (T02) were
commingled with those injected with PBS (T01). The rationale is that if pigs vaccinated
with rPICV-GFP shed the virus, the naïve contact pigs (injected with PBS) would develop
antibodies against GFP. Anti-GFP antibodies were detected in pigs vaccinated with rPICVGFP but not in the contact pigs. Thus, our preliminary data suggest that pigs vaccinated
with rPICV do not spread the pichinde virus horizontally to the contact pigs.
It has been well-documented that vaccination of pigs with an HA-protein-based
vaccine will result in complete protection [25]. Therefore, we included a group of pigs that
were immunized with a purified H3-protein vaccine (T04) in this study for comparative
purposes. As expected, pigs vaccinated with the H3-protein vaccine developed a robust
humoral antibody response, which can be detected at day 21 pv and continued to increase
post boost. On the contrary, H3-specific antibodies were only detected at day 28 pv,
corresponding to day 7 post boost in pigs vaccinated with rPICV-H3 vectored vaccine
(T03). Although pigs in the T03 group developed antibody responses later than those in
the T04 group, their VN- and HAI-antibody titers sharply increased and reached similar
titers compared to those in the T04 group by day 42 pv. In previous studies, the amount of
protein mass used to vaccinate pigs ranged from 0.5 µg to 25 µg per pig per immunization,
which were sufficient to confer sterilizing immunity against the challenge infection with
a homologous H1N1 strain [25,26,44]. In this study, we immunized pigs with 100 µg
purified H3 protein, which was significantly higher than the antigenic dose used in previous
studies [44]. We believe that the earlier antibody response observed in pigs immunized with
the H3-protein vaccine was partially due to the higher antigenic mass used to vaccinate pigs.
None of the pre-vaccination samples had antibodies against IAV-S NP as determined
by a commercial ELISA (Figure 6). Similarly, none of the pre-vaccination samples had
antibodies against HA protein of H3N2 TX98 (Figure 3B). However, samples collected
prior to the study exhibited some level of HAI- and VN-antibody titers against H3N2 TX98
challenge strain (titer ≤ 1:40, equivalent to 5.32 Log2 ). VN- and HAI- titers maintained
the same or slightly declined levels by day 42 pv in pigs injected with PBS (T01) or with
rPICV-GFP (T02). In contrast, these antibody titers rapidly increased in pigs vaccinated
with the H3-protein subunit vaccine (T04) or rPICV-H3 vectored vaccine (T03). Thus, the
VN- and HAI-antibody titer in samples collected pre-study might be due to non-specific
and/or cross-reactivity. It was reported recently that antisera from SARS-CoV-2 patients
could cross-react with the IAV HA protein [46]. The pigs used in this study were unlikely
to be infected with SARS-CoV-2. Instead, they might be pre-exposed to one of the porcine
coronaviruses, which are widely prevalent in swine herds [47].
After challenge infection, viral RNA was not detected in nasal swabs, BALF, and lung
section of pigs in the T04 group. Thus, under the experimental conditions of this study, the
H3-protein vaccine conferred sterilizing immunity against the homologous H3N2 strain.
Two pigs in T03 exhibited detectable levels of IAV-S RNA in their nasal swabs at one
sampling day and one of these two pigs had detectable levels of viral RNA in its BALF
sample at day 5 post challenge. When titrated in MCDK cells, the BALF sample in the
T03 pig that contained IAV-S RNA, as determined by RT-PCR, did not show evidence of
successful IAV-S infection, indicating that the BALF sample was non-infectious or at levels
below the limit of detection of the assay. Statistically, the viral IAV-S RNA copies in nasal
swabs and BALF were not significantly different between the T03 and T04 groups. Likewise,
the lung lesion scores were not different between the T03 and T04 groups, both in terms of
gross- and microscopic-lesion. Collectively, the results suggest that the rPICV-H3 vectored
vaccine confers an equivalent level of protection as compared to the H3-protein vaccine.
ELISA kits detecting antibodies specific to the NP are available for the serodiagnosis of
IAV-S. All pigs in the T03 and T04 groups tested negative by the NP ELISA kit throughout
the course of the study, even though they exhibited high antibody titers against the HA
protein. Thus, pigs vaccinated with the H3-protein vaccine or with the rPICV-H3 vectored
vaccine can be serologically distinguished from those that are naturally infected with IAV-S
by NP ELISA. Therefore, the H3-protein subunit and rPICV-H3 vectored vaccine used
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in this study fulfills the requirement of a DIVA (differentiating infected from vaccinated
animals) vaccine. It should be noted that antibodies against the IAV-S NP protein were not
detected in pigs in the T01 and T02 groups at day 5 post challenge infection (corresponding
to day 48 pv). We believed that this was too soon after infection for pigs in the T01 and T02
groups to mount an antibody response to the NP protein. Indeed, anti-NP antibodies were
only detected in a few pigs that were experimentally inoculated with H1 and H3 IAV-S at
day 14 post infection [48]
5. Conclusions
rPICV is a promising viral vector for the development of IAV-S vaccines. Our results
demonstrate that the rPICV vectored vaccine does not spread horizontally among pigs.
Importantly, pigs vaccinated with the rPICV-H3 vectored vaccine induced HAI and VN
antibodies and were fully protected against challenge infection with a homologous IAV-S
strain. Additional studies are needed to determine whether pigs vaccinated with a rPICVvector expressing HA antigen followed by an infection with a mismatched IAV-S strain can
induce a cross-protective antibody or develop VAERD.
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